Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 1/2017

01-01-2017 | Pathology Review

A critical view on cardiovascular risk in systemic sclerosis

Authors: Antonios Psarras, Stergios Soulaidopoulos, Alexandros Garyfallos, George Kitas, Theodoros Dimitroulas

Published in: Rheumatology International | Issue 1/2017

Login to get access

Abstract

Systemic Sclerosis (SSc) is an autoimmune disorder characterized by microvascular injury and diffuse fibrosis of the skin and internal organs. While macrovascular disease and higher risk for cardiovascular events are well documented in other systemic rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, the presence and extent of atherosclerosis among patients with SSc is yet to be established. Primary cardiac involvement, due to impairment of coronary microvascular circulation and myocardial fibrosis, considerably affects prognosis and life expectancy of individuals with SSc, representing one of the leading causes of death in this population. On the other hand the existence and prevalence of atherosclerotic coronary disease remains an issue of debate as studies comparing structural and morphological markers of atherosclerosis and cardiovascular events between SSc patients and the general population have yielded controversial results. The aim of this review is to summarize recent literature about the prevalence of cardiovascular disease in SSc, review the surrogate markers of CVD that have been evaluated and examine whether common pathogenic mechanisms exist between SSc and macrovascular disease.
Literature
1.
Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24:165–170CrossRefPubMed
2.
Chifflot H et al (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37:223–235CrossRefPubMed
3.
4.
Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD (2012) Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. Curr Pharm Des 18:1457–1464CrossRefPubMed
5.
6.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417CrossRefPubMed
7.
Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106CrossRefPubMed
8.
Kitas GD, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8–14CrossRefPubMed
9.
Hollan I et al (2013) Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12:1004–1015CrossRefPubMed
10.
Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11:693–704CrossRefPubMed
11.
Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ et al (2008) Cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 67:64–69CrossRefPubMed
12.
Zegos T, Kitas G, Dimitroulas T (2016) Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis 8:86–101CrossRef
13.
Faccini A, Kaski JC, Camici PG (2016) Coronary microvascular dysfunction in chronic nflammatory rheumatoid diseases. Eur Heart J 37:1799–1806CrossRefPubMed
14.
Sharma A, Gopalakrishnan D, Kumar R, Vijayvergiya R, Dogra S (2013) Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study. Int J Rheum Dis 16:667–673CrossRefPubMed
15.
Medina G et al (2003) Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62:607–610CrossRefPubMedPubMedCentral
16.
Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E et al (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49:295–307CrossRef
17.
Sandoo A, van Zanten JJ, Toms TE, Carroll D, Kitas GD (2012) Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord 13:127CrossRefPubMedPubMedCentral
18.
Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA (2005) Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 64:765–766CrossRefPubMed
19.
Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nightingale P, Koutedakis Y, Kitas GD (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14:R160CrossRefPubMedPubMedCentral
20.
Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD (2012) Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 18:1543–1555CrossRefPubMed
21.
Nurmohamed MT, Kitas G (2011) Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Annals of the rheumatic diseases. Ann Rheum Dis 70:881–883CrossRefPubMed
22.
Dimitroulas T, Sarafidis P, Roma V, Karagiannopoulou G, Kapoulas S, Dimitroula H et al (2010) Scleroderma renal crisis accompanied by new-onsetpulmonary arterial hypertension: an acute systemic endothelial injury? Casereport and literature. Inflamm Allergy Drug Targets 9:313–318CrossRefPubMed
23.
Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M et al Spanish Scleroderma Study Group (SSSG); Autoimmune Diseases Study Group (GEAS); Spanish Society of Internal Medicine (SEMI) (2015) Registry of the Spanish Network for systemic sclerosis: survival, prognostic factors, and causes of death. Medicine (Baltimore) 94:e1728
24.
Nussinovitch U, Shoenfeld Y (2011) Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 10:259–266CrossRefPubMed
25.
Psarras A et al (2014) Giant cell arteritis and systemic sclerosis: a rare overlap syndrome. Rheumatol Rep 6:1CrossRef
26.
Hupp SL (1989) Giant cell arteritis associated with progressive systemic sclerosis. J Clin Neuroophthalmol 9:126–130PubMed
27.
Jacobsen S et al (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750–755CrossRefPubMed
28.
29.
Tyndall AJ et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815CrossRefPubMed
30.
Dave AJ et al (2014) Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:323–327CrossRef
31.
Man A et al (2013) The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis 72:1188–1193CrossRefPubMed
32.
Ngian GS et al (2012) Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 71:1980–1983CrossRefPubMed
33.
34.
Aviña-Zubieta JA, Man A, Yurkovich M, Huang K, Sayre EC, Choi HK (2016) Early cardiovascular disease after the diagnosis of systemic sclerosis. Am J Med 129:324–331CrossRefPubMed
35.
D’Angelo WA et al (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428–440CrossRefPubMed
36.
Youssef P et al (1995) Limited scleroderma is associated with increased prevalence of macrovascular disease. J Rheumatol 22:469–472PubMed
37.
Komocsi A et al (2010) Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 69:202–205CrossRefPubMed
38.
Derk CT, Jimenez SA (2007) Acute myocardial infarction in systemic sclerosis patients: a case series. Clin Rheumatol 26:965–968CrossRefPubMed
39.
Khurma V et al (2008) A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum 59:591–597CrossRefPubMed
40.
Tarek G et al (2006) Coronary angiographic findings in asymptomatic systemic sclerosis. Clin Rheumatol 25:487–490CrossRef
41.
Lekakis J et al (1998) Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J 136:905–912CrossRefPubMed
42.
Sherer Y et al (2007) Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann N Y Acad Sci 1108:259–267CrossRefPubMed
43.
Bartoli F et al (2007) Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology (Oxford) 46:772–775CrossRef
44.
Bartoli F et al (2007) Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 1108:283–290CrossRefPubMed
45.
Kaloudi O et al (2007) Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. Rheumatology (Oxford) 46:412–416CrossRef
46.
Kumar U, Verma N, Kumar AK, Hari S, Yadav R, Sreenivas V et al (2010) Endothelial dysfunction in Indian patients with systemic sclerosis[abstract]. Ann Rheum Dis 69(Suppl 3):692
47.
Tsifetaki N et al (2010) Subclinical atherosclerosis in scleroderma patients. Scand J Rheumatol 39:326–329CrossRefPubMed
48.
Hettema ME, Zhang D, de Leeuw K, Stienstra Y, Smit AJ, Kallenberg CG, Bootsma H (2008) Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 10:R49CrossRefPubMedPubMedCentral
49.
Roustit M et al (2008) Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol 35:1576–1583PubMedPubMedCentral
50.
Piccione MC et al (2011) Early identification of vascular damage in patients with systemic sclerosis. Angiology 62:338–343CrossRefPubMed
51.
Liu J et al (2011) Preferential macrovasculopathy in systemic sclerosis detected by regional pulse wave velocity from wave intensity analysis: comparisons of local and regional arterial stiffness parameters in cases and controls. Arthritis Care Res (Hoboken) 63:579–587CrossRef
52.
53.
Schiopu E et al (2014) Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology (Oxford) 53:704–713CrossRef
54.
Ozen G, Inanc N, Unal AU, Korkmaz F, Sunbul M, Ozmen M et al (2016) Subclinical Atherosclerosis in systemic sclerosis: not less frequent than rheumatoid arthritis and not detected with cardiovascular risk indices. Arthritis Care Res (Hoboken) 2016 Feb 11 [Epub ahead of print]
55.
Szucs G et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis–relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759–762CrossRef
56.
Rollando D et al (2010) Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol 37:1168–1173CrossRefPubMed
57.
Stucker M et al (2000) Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 5:295–302PubMed
58.
Trostle DC et al (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31:393–400CrossRefPubMed
59.
60.
Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas GD (2014) Micro- and macro-vascular treatment targets in scleroderma heart disease. Curr Pharm 20:536–544CrossRef
61.
Zakopoulos NA et al (2003) Systemic sclerosis is not associated with clinical or ambulatory blood pressure. Clin Exp Rheumatol 21:199–204PubMed
62.
Zeng Y et al (2012) Macrovascular involvement in systemic sclerosis: evidence of correlation with disease activity. Clin Exp Rheumatol 30(2 Suppl 71):S76–S80PubMed
63.
Lippi G et al (2006) Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. Clin ChimActa 364(1–2):345–348CrossRef
64.
Borba EF et al (2005) Lipoprotein profile in limited systemic sclerosis. Rheumatol Int 25:379–383CrossRefPubMed
65.
66.
Abraham DJ, Krieg T, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford)48(Suppl 3):iii3-7
67.
Assaly R et al (2001) Initial evidence of endothelial cell apoptosis as a mechanism of systemic capillary leak syndrome. Chest 120:1301–1308CrossRefPubMed
68.
Muro Y et al (2009) An evaluation of the efficacy of the toe brachial index measuring vascular involvement in systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol 27(3 Suppl 54):26–31PubMed
69.
Sgonc R et al (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562CrossRefPubMed
70.
Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE (2015) Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 2015 Oct 25 [Epub ahead of print]
71.
Muresan L, Petcu A, Pamfil C, Muresan C, Rinzis M, Mada RO (2016) Cardiovascular profiles of scleroderma patients arrhythmias and conduction disorders. Acta Reumatol Port 41:26–39PubMed
72.
Cannarile F, Valentini V, Mirabelli G, Alunno A, Terenzi R, Luccioli F (2015) Cardiovascular disease in systemic sclerosis. Ann Transl Med 3:8PubMedPubMedCentral
73.
Fernandes F et al (2003) Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 9:311–317CrossRefPubMed
74.
Lekakis J, Mavrikakis M, Emmanuel M, Prassopoulos V, Papazoglou S, Papamichael C et al (1997) Cold-induced coronary Raynaud’s phenomenon in patients with systemic sclerosis. Clin Exp Rheumatol 16:135–140
75.
Gustafsson R, Kazzam E, Mannting F, Waldenström A, Hällgren R (1989) Cold-induced reversible myocardial ischaemia in systemic sclerosis. The Lancet 334:475–479CrossRef
76.
Long A, Duffy G, Bresnihan B (1986) Reversible myocardial perfusion defects during cold challenge in scleroderma. Rheumatology 25:158–161CrossRef
77.
Mueller KA, Mueller II, Eppler D, Zuern CS, Seizer P, Kramer U (2015) Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS ONE 10:e0126707CrossRefPubMedPubMedCentral
78.
Kahan A, Nitenberg A, Foult JM, Amor B, Menkes CJ, Devaux JY et al (1985) Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 28:637–646CrossRefPubMed
79.
Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens GR (1984) Rodnan GP (1984) Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. NEJM 310:142–148CrossRefPubMed
80.
81.
Can I, Onat AM, Aytemir K, Akdogan A, Ureten K, Kiraz S et al (2009) Detecting subclinical biventricular impairment in scleroderma patients by use of pulsed-wave tissue Doppler imaging. Tex Heart Inst J 1:36
82.
Schattke S, Knebel F, Grohmann A, Dreger H, Kmezik F, Riemekasten G et al (2010) Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. Cardiovasc Ultrasound 8:1CrossRef
83.
Dimitroulas T, Giannakoulas G, Papadopoulou K, Karvounis H, Dimitroula H, Koliakos G et al (2010) Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 37:993–999CrossRefPubMed
84.
Mavrogeni S, Sfikakis PP, Dimitroulas T, Koutsogeorgopoulou L, Karabela G, Katsifis G et al (2015) Imaging patterns of cardiovascular involvement in mixed connective tissue disease evaluated by cardiovascular magnetic resonance. Inflamm Allergy Drug Targets 4:111–116
85.
Barison A et al (2015) Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 16:74–80CrossRefPubMed
86.
Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Rai AB, Matthews PM et al (2014) Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis—a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson 16:21CrossRefPubMedPubMedCentral
87.
Mavrogeni S, Bratis K, Karabela G et al (2015) Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. Inflamm Allergy Drug Targets 14:29–36CrossRefPubMed
88.
Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, Gabriel S et al (2016) Cardiovascular magnetic resonance in rheumatology: current status and recommendations for use. Int J Cardiol 217:135–148CrossRefPubMed
89.
Hachulla E, Gressin V, Guillevin L et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792–3800CrossRefPubMed
90.
Hunzelmann N, Genth E, Krieg T et al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 47:1185–1192CrossRef
91.
Avouac J, Airò P, Meune C et al (2010) Prevalence of pulmonary hyper- tension in systemic sclerosis in European Caucasians and metaana- lysis of 5 studies. J Rheumatol 37:2290–2298CrossRefPubMed
92.
Phung S, Strange G, Chung LP et al (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39:682–691CrossRefPubMed
93.
Sanz J, Kariisa M, Dellegrottaglie S, Prat-Gonzalez S, Garcia MJ, Fuster V, Rajagopalan S (2009) Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. J Am Coll Cardiol Img 2:286–295CrossRef
94.
Fisher MR, Mathai SC, Champion HC et al (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54:3043–3050CrossRefPubMed
95.
Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 29:957–964CrossRefPubMed
96.
Tongers J, Schwerdtfeger B, Klein G et al (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153:127–132CrossRefPubMed
97.
Mathai SC, Bueso M, Hummers LK et al (2010) Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35:95–104CrossRefPubMed
98.
Allanore Y, Meune C, Vonk MC et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. Ann Rheum Dis 69:218–221CrossRefPubMed
99.
Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G (2007) Relation-ship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 19:200–207CrossRefPubMed
100.
Koka S, Das A, Salloum FN, Kukreja RC (2013) Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med 60:80–88CrossRefPubMed
101.
Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC (2012) Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One7:e45243CrossRefPubMedPubMedCentral
102.
Metsios G, Lahart IM (2015) Exercise as medicine in rheumatoid arthritis. Mediterr J Rheumatol 26:54–61
103.
John H, Carroll D, Kitas GD (2011) Cardiovascular education for people with rheumatoid arthritis: what can existing patient education programmes teach us? Rheumatology (Oxford) 50:1751–1759CrossRef
104.
Domsic RT, Dezfulian C, Shoushtari A, Ivanco D, Kenny E, Kwoh CK et al (2014) Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemics clerosis patients. Clin Exp Rheumatol 32(6 Suppl 86):S-154-60
105.
Turiel M, Gianturco L, Ricci C, Sarzi-Puttini P, Tomasoni L, Colonna Vde G et al (2013) Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. Arthritis Care Res (Hoboken) 2013(65):274–280CrossRef
Metadata
Title
A critical view on cardiovascular risk in systemic sclerosis
Authors
Antonios Psarras
Stergios Soulaidopoulos
Alexandros Garyfallos
George Kitas
Theodoros Dimitroulas
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3530-3

Other articles of this Issue 1/2017

Rheumatology International 1/2017 Go to the issue

Review on RMD

Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms

Cases with a Message

Takayasu arteritis (TA) first presenting with intestinal ischemia: a case report and review of gastrointestinal tract involvement (ischemic and non-ischemic) associated with TA

Imaging

Progression of noncalcified and calcified coronary plaque by CT angiography in SLE

Pathology Review

Cardiac involvement in juvenile idiopathic arthritis

Erratum

Erratum to: Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival

Observational Research

Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits